GSK PLC-SPON ADR (GSK) 33.76 -0.23 (-0.68%)
33.76 -0.23 (-0.68%)
US37733W2044 - ADR - After market: 33.95 +0.19 (+0.56%)
Fundamental Rating
Overall GSK gets a fundamental rating of 5 out of 10. We evaluated GSK against 253 industry peers in the Pharmaceuticals industry. While GSK has a great profitability rating, there are some concerns on its financial health. GSK is valued correctly, but it does not seem to be growing.
Profitability
Profitability Rating
GSK's Return On Assets of 22.72% is amongst the best returns of the industry. GSK outperforms 97% of its industry peers. The industry average Return On Assets is -41.45%.
GSK's Return On Equity of 149.74% is amongst the best returns of the industry. GSK outperforms 97% of its industry peers. The industry average return on equity is 19.66%.
GSK's Profit Margin of 43.54% is amongst the best returns of the industry. GSK outperforms 97% of its industry peers. The industry average Profit Margin is -97.50%.
The Piotroski-F score of GSK is 5.00. This is a neutral score and indicates average health and profitability for GSK.
VS Industry
ROA (22.72%) VS Industry: 97% outperformed.
-1,292.14
111.39
ROE (149.74%) VS Industry: 97% outperformed.
1.38
176.97
Profit Margin (43.54%) VS Industry: 97% outperformed.
-53,337.68
1,968.82
Valuation
Valuation Rating
The Price/Earnings Ratio is 9.03, which indicates a very decent valuation of GSK.
GSK's Price/Earning Ratio is a bit cheaper than the industry average which is at 13.52.
The Forward Price/Earnings Ratio of 9.62 indicates a rather cheap valuation of GSK.
GSK's PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
With a price book ratio of 6.21, GSK is valued correctly.
When comparing the price book ratio of GSK to the average industry price book ratio of 1.48, GSK is valued more expensive than its industry peers. 89% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of GSK to the average industry ratio of 3.45, GSK is valued more expensive than its industry peers.
VS Industry
Price/Earnings (9.03) VS Industry: 66% outperformed.
82.50
0.02
Price/Book (6.21) VS Industry: 11% outperformed.
309.96
0.10
Enterprise Value/ EBITDA (6.52) VS Industry: 40% outperformed.
246.53
0.01
Growth
Growth Rating
The Earnings Per Share has grown by an nice 11.18% over the past year.
Measured over the past 5 years, GSK shows a small growth in Earnings Per Share. The EPS has been growing by 6.68% on average per year.
GSK is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 4.97% yearly.
The Revenue has been growing slightly by 9.97% in the past year.
GSK shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 4.11% yearly.
The Revenue is expected to decrease by -1.59% on average over the next 5 years.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 6.68% | 5.82% | 11.18% | -6.65% | 1.04% | 3.44% | 4.97% |
| Revenue | 4.11% | 3.44% | 9.97% | -15.75% | -6.99% | -2.59% | -1.59% |
Health
Health Rating
When comparing the Altman-Z score to an average industry score of -0.52, GSK is in better financial health than the average industry peer.
GSK has a Piotroski-F score of 5.00. This indicates an average health and profitability for GSK.
A Current Ratio of 0.97 indicates that GSK may have some problems paying its short term obligations.
When comparing the Current Ratio of GSK to the average industry Current Ratio of 3.52, GSK is less able to pay its short term obligations than its industry peers. 90% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.74 indicates that GSK may have some problems paying its short term obligations.
When comparing the Quick Ratio of GSK to the average industry Current Ratio of 2.88, GSK is less able to pay its short term obligations than its industry peers. 89% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, GSK is requires more financing than its industry peers. 95% of its industry peers have a better Debt to Equity Ratio.
GSK has an Altman-Z score of 1.70. This is a bad value and indicates that GSK is not financially healthy and even has some risk of bankruptcy.
VS Industry
Debt/Equity (2.11) VS Industry: 5% outperformed.
59.36
0.00
Quick Ratio (0.74) VS Industry: 11% outperformed.
-2.73
76.82
Current Ratio (0.97) VS Industry: 10% outperformed.
0.09
76.82
Altman-Z (1.7) VS Industry: 69% outperformed.
-219.98
112.97
Dividend
Dividend Rating
With a Yearly Dividend Yield of 7.31%, GSK is a good candidate for dividend investing.
GSK's Dividend Yield is rather good when compared to the industry average which is at 2.79. GSK pays more dividend than 100% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.47, GSK pays a better dividend.
27.47% of the earnings are spent on dividend by GSK. This is a low number and sustainable payout ratio.
GSK has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of GSK decreases each year by -7.17%.
VS Industry
Dividend Yield (7.31%) VS Industry: 100% outperformed.
0.69
7.31
GSK PLC-SPON ADR33.76
NYSE:GSK (11/28/2022, 7:04:00 PM)-0.23 (-0.68%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Pharmaceuticals | ||
| Earnings (Last) | 11-02 2022-11-02/bmo | Earnings (Next) | 02-01 2023-02-01 |
| Ins Owners | N/A | Inst Owners | 0.57% |
| Market Cap | 68.66B | Analysts | 70.27 |
| PE | 9.03 | Fwd PE | 9.62 |
| PEG (NY) | N/A | PEG (5Y) | 1.35 |
| P/S | 1.81 | P/B | 6.21 |
| EV/EBITDA | 6.52 | ||
| Dividend Yield | 7.31% | Dividend Growth | -7.17% |
| DP | 27.47% | Ex-Date | 11-17 2022-11-17 (0.3171217) |
| EPS 1Y | 11.18% | EPS 3Y | 5.82% |
| EPS 5Y | 6.68% | EPS growth Q2Q | 2.51% |
| EPS Next Y | -6.65% | EPS Next 2Y | 1.04% |
| EPS Next 3Y | 3.44% | EPS Next 5Y | 4.97% |
| Revenue growth 1Y | 9.97% | Revenue growth 3Y | 3.44% |
| Revenue growth 5Y | 4.11% | Revenue growth Q2Q | 18.14% |
| Revenue Next Year | -15.75% | Revenue Next 2Y | -6.99% |
| Revenue Next 3Y | -2.59% | Revenue Next 5Y | -1.59% |
| Current Ratio | 0.97 | Quick Ratio | 0.74 |
| Altman-Z | 1.7 | F-Score | 5 |
| Debt/Equity | 2.11 | WACC | 7.11% |
| ROIC/WACC | 10.62 | ||
| ROA | 22.72% | ROE | 149.74% |
| ROICexgc | 75.5% | ROIC | 18.06% |
| PM | 43.54% | OM | 24.37% |
| Asset Turnover | 0.52 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA